



A non-profit organization

10-30-99

Food and Drug Administration  
Dockets Management Branch (HFA-305)  
5630 Fishers Lane, #1061  
Rockville, MD 20852

Dear Sir/Madam,

This is our written comment on Proposed Rule 21CFR Part 210, 211, 820 and 1271 (Docket No. 97N-484S) "Suitability Determination for Donors of Human Cellular and Tissue-Based Products", published in the Federal Register vol. 64, No. 189, September 30, 1999.

Proposed Rule 1271.85 on page 92705 reads:

"The following list represent FDA's current thinking on the appropriate FDA-licensed, approved or cleared screening tests that should be used to adequately and appropriately reduce the risk of transmission of relevant communicable disease agents or diseases:

- (3) HBV: FDA-licensed screening test for hepatitis B surface antigen (HBsAg)

On the page 92706 the proposed rule reads:

"In the case of HBV there are two types of screening tests: A test for the surface antigen and a test for the core antibody".

Further on page 92706 the proposed rule reads:

"For example, a repeatedly reactive core antibody test for HBV, although not required, would make the donor unsuitable"

FDA should consider the following addition to the Proposed Rule:

If the use of an FDA-cleared serological test for HBsAg is reported as NEGATIVE (NON-REACTIVE) and the use of an FDA-cleared serological test for Hepatitis B core antibody (HBcAb) is reported as POSITIVE (REACTIVE), the clarification of donor potential Hepatitis B infectivity and Hepatitis B immune status can be performed by using both of the following two FDA-cleared serological tests:

- a) HBcAb IgM and
- b) Hepatitis B surface Antibody (HBsAb)

**Pacific Coast Tissue Bank**

2500-19 So. Flower Street • Los Angeles, Ca. 90007 • Ph# 213 745-5560 Fax# 213 745-3031

97N-484S

C6

In the following serological picture:

HBsAg - NEGATIVE  
HBcAb - POSITIVE  
HBcAb IgM - NEGATIVE  
HBsAb - POSITIVE

donor has had Hepatitis B infection in the past which has resolved. Non-hepatic tissue from such donor can not transmit Hepatitis B and donor should be considered suitable. It must be mentioned that 95-99% of adults contracting hepatitis B infection progress to complete recovery with development of established protective antibody (HBsAb). Enclosed is a study published in The Lancet in 1974. This study was supported by a grant from National Heart and Lung Institute, Bethesda, Maryland and performed in collaboration with the Blood Bank Department of National Institute of Health

This study examined the risk of transfusing blood containing HBsAb. Since this study was performed prior to Hepatitis B vaccine being available, all donors with positive HBsAb had prior infection with Hepatitis B virus and by definition also had positive HBcAb. The study has found that HBsAb positive blood does not transmit Hepatitis B to the recipients.


Presence of HBcAb (IgG) is not a SCREENING TEST for Hepatitis B infectivity as the proposed rule states, but a HISTORICAL TEST indicating previous infection with Hepatitis B virus which in the vast majority of cases terminates in recovery and development of protective immunity.

Sincerely

Eli Gendler MD  
Medical Director  
Pacific Coast Tissue Bank



Tillman M. Moore MD  
Medical Director  
Pacific Coast Tissue Bank



ATTACHMENT



of the donor units received by these patients contained detectable HB<sub>s</sub>Ag. Of the 362 transfusion recipients, 23 (6%) developed 25 episodes of hepatitis; only 4 of these 25 episodes were serologically related to H.B.V. Based on the absence of antibody to HB<sub>s</sub>Ag (anti-HB<sub>s</sub>) prior to transfusion, 278 of the patients were considered susceptible to H.B.V. infection. Of these susceptible patients, 133 received at least one unit of blood containing anti-HB<sub>s</sub>; when compared with the 145 who did not receive anti-HB<sub>s</sub>, there was no significant difference in biochemical or overt hepatitis B (3/133 vs. 1/145), in serological response to H.B.V. (5/133 vs. 5/145), or in hepatitis unrelated to H.B.V. (11/133 vs. 6/145). It is concluded that blood containing detectable anti-HB<sub>s</sub> carries no increased risk of transmitting hepatitis B compared with blood which lacks this antibody.

### Introduction

THE risk of developing post-transfusion hepatitis has been markedly reduced by the adoption of universal testing of donor bloods for hepatitis-B antigen (HB<sub>s</sub>Ag) and by decreased utilisation of commercial blood.<sup>1</sup> However, despite the exclusion of HB<sub>s</sub>Ag-positive blood donors, some HB<sub>s</sub>Ag-positive post-transfusion hepatitis continues to occur.<sup>1-4</sup> This could be due to the administration of HB<sub>s</sub>Ag or other specific antigens associated with hepatitis-B virus (H.B.V.) in quantities below the threshold of current detection methods.<sup>4-6</sup> HB<sub>s</sub>Ag could also escape detection if that antigen were complexed to and therefore masked by antibody to it (anti-HB<sub>s</sub>). In the latter instance, one might detect only circulating anti-HB<sub>s</sub> in blood that is potentially infectious.<sup>9</sup> In addition, since the presence of anti-HB<sub>s</sub> indicates past exposure to the hepatitis-B virus, the finding of this antibody might be just as valid a reason for donor exclusion as is the currently accepted exclusion based upon a history of clinical hepatitis.<sup>10,11</sup>

Despite these theoretical considerations, blood containing anti-HB<sub>s</sub> is still transfused and the few studies performed to date have failed to demonstrate increased infectivity of such antibody-containing blood; the issue, however, is not totally resolved because the number of individuals followed has been small or because the studies have lacked serological data to assess susceptibility to H.B.V.<sup>12-14</sup> Furthermore, the exclusion of donors with anti-HB<sub>s</sub> would severely reduce blood availability, since 5-20% of volunteer donors have anti-HB<sub>s</sub> detectable by present, sensitive techniques.<sup>10</sup> We have combined data from three prospective studies of post-transfusion hepatitis in order to determine more clearly if donor blood containing anti-HB<sub>s</sub> carries a significantly greater risk of transmitting hepatitis B than blood which lacks this antibody.

### Patients and Methods

#### Study of Studies

Studies were performed in three medical centres: the Washington University Medical Center in St. Louis, the College of Medicine-Ben Taub General Hospital in Houston, and the National Institutes of Health Clinical

Center in Bethesda. The designs of these studies have previously been described.<sup>1-4</sup> Patients were assessed at the Washington University and the Ben Taub General Hospital beginning August, 1971, and at the Clinical Center Blood Bank beginning February, 1970. All patients successfully completed a six-month follow-up by November, 1973.

The Washington University study and the Clinical Center Blood Bank study followed cardiovascular-surgery patients, while the Baylor study followed a randomised sample of general-surgery patients who received blood-transfusions at Ben Taub General Hospital. The three studies are very comparable in design and are summarised in table 1. All donor units were tested for antigen and antibody, and recipients were followed at least every two weeks for three months and every month thereafter for three months. Washington University patients were followed every two weeks for six months. Patients were excluded if they received transfusions on more than one occasion or if they received blood derivatives other than plasma, red cells, or whole blood.

### Definitions

Hepatitis was diagnosed when, between two and twenty-six weeks following transfusion, alanine aminotransferase (S.G.P.T.) and/or aspartate aminotransferase (S.G.O.T.) rose to at least 2 times the upper limit of normal on 2 successive occasions at least a week apart, and when there was no other obvious explanation for the enzyme elevation. Icterus was defined as a bilirubin greater than 2 mg. per 100 ml. Hepatitis B was diagnosed when, during an episode of hepatitis, HB<sub>s</sub>Ag was detected, and/or the patient developed antibody seroconversion. Seroconversion was the de-novo appearance, and persistence, of anti-HBs twenty-one or more days after transfusion in a patient having no pre-existing antibody to the hepatitis-B antigen. Anamnestic response was a fourfold or greater rise of anti-HBs occurring within fourteen days following transfusion in a patient with pre-existing antibody. Serological response only was defined as seroconversion, or anamnestic response, or development of HB<sub>s</sub>Ag in a patient who did not develop enzyme elevations indicative of hepatitis. Exposure was measured by development of hepatitis B and/or serological response to H.B.V.

### Technique

All donors in this study were tested for HB<sub>s</sub>Ag by counterelectrophoresis<sup>15,16</sup> prior to transfusion. After transfusion, stored sera from these donors were retested by radioimmunoassay. At Washington University and at Baylor subsequent testing was performed by double-antibody radioimmunoassay (R.I.A.-D.A.)<sup>17-19</sup> and by solid-phase radioimmunoassay (Ausria).<sup>20</sup> At the Clinical Center most specimens, but not all, were retested by Ausria. Patients who were HB<sub>s</sub>Ag-positive prior to transfusion or who received blood containing HB<sub>s</sub>Ag were excluded from analysis in this report.

Anti-HBs was measured by R.I.A.-D.A.<sup>18,21</sup> and by passive haemagglutination (P.H.A.).<sup>22</sup> These methods have recently been compared.<sup>23</sup> Washington University initially tested for anti-HBs by R.I.A.-D.A. and confirmed positives by P.H.A.; Baylor screened for antibody by P.H.A. and confirmed positives by R.I.A.-D.A. The Clinical Center Blood Bank tested for antibody by R.I.A.-D.A. initially in the study and by P.H.A. later.

Statistical analysis was performed by Dr Marian Fisher of the Biometrics Research Branch, National Heart and Lung Institute, using Fisher's exact test, two tails. Statistical significance in this study is defined as a *p* value of 0.05 or less.

### BLOOD HEPATITIS-B EN

VEY J. ALTER  
L. V. HOLLAND  
H. L. MELNICK

University of  
Clinical Center  
Department of  
Medicine; and  
Blood Diseases and  
Lung Institute

recipients, who  
ly negative  
ere prospective  
gical evidence  
a.v.) and for  
i to a.v. Now

support; the ph  
nd Mrs. C. Pond  
their assistance.  
started in earlier  
D. N. Nabarro, and  
supported by  
and Peel Medica

sed to R. C. T.

D. N. Br. med J. 197  
3, 1, 1483.  
D. N. Br. med J. 197  
er, R. C. Acta endoc  
1969, 172, 894  
e press).

## Results

362 patients whose pre-transfusion sera were all initially HB<sub>s</sub>Ag-negative were followed for six months after transfusion. Sera from all of their donors were tested for HB<sub>s</sub>Ag and anti-HB<sub>s</sub>. Table 1 shows the number of patients and the average number of units received per patient at each participating centre. The proportion of donors with antibody ranged from 9% at the Clinical Center to 15% at Ben Taub, whereas the proportion of recipients with pre-transfusion antibody ranged from 10% to 29%.

Table II provides the clinical and serological response to blood-transfusion in the 362 blood recipients. Among these patients, 25 episodes of hepatitis occurred, 4 of which were ascribed to type-B hepatitis. 2 patients had two distinct episodes of hepatitis—a short-incubation, non-type-B, anicteric illness, and a subsequent long-incubation, HB<sub>s</sub>Ag-positive, icteric illness. 7 additional patients had a serological response to H.B.V. without biochemical evidence of hepatitis; 1 developed HB<sub>s</sub>Ag alone, 5 had seroconversion, and 1 had an anamnestic response. All 4 cases of HB<sub>s</sub>Ag-positive hepatitis were icteric compared with only 5 of 21 non-B hepatitis cases. There were no fatalities attributable to hepatitis in any of the patients followed.

TABLE 1—CHARACTERISATION OF DONORS AND PATIENTS IN EACH STUDY CENTRE (ALL DONOR UNITS WERE NEGATIVE FOR HB<sub>s</sub>Ag\* AND WERE TESTED FOR ANTI-HB<sub>s</sub>)

Participating centre	No. of recipients followed six months	Average no. of donor units transfused per patient	Commercial blood (%)	Donors anti-HB <sub>s</sub> positive (%)	Recipients anti-HB <sub>s</sub> positive before transfusion (%)
Washington University Medical Center	105	11.3	0	11	22
Baylor-Ben Taub General Hospital	208	2.8	15†	15	29
Clinical Center Blood Bank	49	18.5	0	9	10

\* All donor units were tested by counter-electrophoresis prior to transfusion; subsequently at Washington University and at Baylor all units, and at the Clinical Center most units, were retested by radioimmunoassay.

† 15% of the blood was obtained from a commercial blood-bank service but only one-fourth of these donors were paid.

TABLE II—CLINICAL AND SEROLOGICAL RESPONSE OF RECIPIENTS TO BLOOD WHICH CONTAINED OR LACKED ANTI-HB<sub>s</sub>

Pre-transfusion serological status of recipient	Total no. of recipients	Donor blood contains:		No. of recipients	Total cases of hepatitis	Confirmed exposure to H.B.V.				Total non-type-hepatitis
		HB <sub>s</sub> Ag	Anti-HB <sub>s</sub>			Total hepatitis-B cases*	Serological response only		Total hepatitis-B exposure	
							HB <sub>s</sub> Ag	Anti-HB <sub>s</sub>		
No HB <sub>s</sub> Ag or anti-HB <sub>s</sub>	278	—	—	145	7†	1 (1)†	1	3	5	6 (0)†
		—	—	133	14†	3 (3)†	0	2	5	11 (4)*
Pre-existing anti-HB <sub>s</sub> only	84	—	—	45	2	0	0	0	0	2 (1)
		—	—	39	2	0	0	1	1	2 (0)
Totals	362			362	25	4 (4)	1	6	11	21 (5)
							7			

\* Numbers in parentheses indicate numbers of total cases which were icteric.

† 2 episodes of hepatitis were diagnosed in each of 2 patients; the first episode in each patient was non-type-B and the second was type-B hepatitis.

We first analysed the entire recipient population (362 patients) in order to compare the clinical and serological outcome in those who received antibody-containing blood with those who did not (table II). There was no significant difference in measured H.B.V. exposure (5/172 vs. 5/190) nor in hepatitis unrelated to H.B.V. (13/172 vs. 8/190). Patients were then analysed separately according to whether or not they had anti-HB<sub>s</sub> prior to transfusion. 278 recipients did not have pre-existing anti-HB<sub>s</sub>; 145 of these recipients received only blood which lacked anti-HB<sub>s</sub>, while 133 received at least one unit of blood containing anti-HB<sub>s</sub>. When these groups were compared there was again no significant difference in measured H.B.V. exposure (5/145 vs. 5/133), in hepatitis B (1/145 vs. 3/133), or in hepatitis unrelated to H.B.V. (6/145 vs. 11/133).

84 patients had antibody to HB<sub>s</sub>Ag at the time of transfusion. 4 of these patients developed hepatitis, but none was serologically related to H.B.V. An anamnestic serological response to H.B.V. was observed in only 1 of the recipients with pre-existing anti-HB<sub>s</sub>; that patient received blood containing anti-HB<sub>s</sub>.

Among the 362 recipients in this study there were 21 episodes of hepatitis in which neither HB<sub>s</sub>Ag nor anti-HB<sub>s</sub> could be demonstrated. These non-type-B cases showed no significant association with the presence or absence of pre-existing anti-HB<sub>s</sub> in the recipient or with the presence or absence of anti-HB<sub>s</sub> in donor blood.

35 additional susceptible patients were followed by the Clinical Center Blood Bank. They were not included in the preceding analysis because greater than 90%, but not all, of their donor sera were tested for anti-HB<sub>s</sub>.

All donors were tested for HB<sub>s</sub>Ag and were found to be negative. Each of these 35 patients received at least one unit of blood containing anti-HB<sub>s</sub>. A negative control group for these patients cannot be presented because of the uncertain antibody status of untested donors. None the less, among these 35 additional recipients of blood containing anti-HB<sub>s</sub>, none developed type-B hepatitis or serological response to H.B.V.; 2 developed hepatitis unrelated to H.B.V.

## Discussion

Seeff et al.,<sup>14</sup> in a preliminary report of a study of over 2000 blood recipients, found that the risk of

developing receiving a HB<sub>s</sub> (1.4% risk after 1 or antibody less hepatitis contained c

Goldfield of anti-HI 103 control nor HB<sub>s</sub>Ag did not de transfusion 37 recipient recipients c that antibo risk of tran the pre-tra was not sta bility to H transfusion not given a blood to el or to cause be ascertain

The pres developer of serologic of these dat was initial presence of When the neither the serological c in those tra did not rec lack of stati those patier ably suscep pre-existing No case occurred ar anti-HB<sub>s</sub> in among the Although tl nificant, the which indic in patients unusual.

The total was 6.4% hepatitis B; related to H ship betwee and the pre the recipien We concl the risk of c ment of H fusion of an greater than of blood wh do not supp anti-HB<sub>s</sub>.

This work

developing overt or biochemical hepatitis B after receiving at least one unit of blood containing anti-HB<sub>s</sub> (1.4%) was not significantly greater than the risk after receiving blood without detectable antigen or antibody (0.6%); both groups had significantly less hepatitis than a third group receiving blood which contained only HB<sub>s</sub>Ag (13.7%).

Goldfield et al.<sup>24</sup> prospectively studied 29 recipients of anti-HB<sub>s</sub>-containing, HB<sub>s</sub>Ag-negative blood and 103 controls who received blood with neither anti-HB<sub>s</sub> nor HB<sub>s</sub>Ag; recipients of antibody-containing blood did not demonstrate an increased frequency of post-transfusion hepatitis. Gocke and Panick<sup>12</sup> compared 37 recipients of anti-HB<sub>s</sub>-containing blood with 136 recipients of anti-HB<sub>s</sub>-negative blood, and concluded that antibody-containing blood carried no increased risk of transmitting hepatitis B. In all three studies, the pre-transfusion antibody status of the recipients was not stated and therefore their presumed susceptibility to H.B.V. was unknown. In addition, the post-transfusion serological response of the patients was not given and thus the ability of anti-HB<sub>s</sub>-containing blood to elicit an HB<sub>s</sub>Ag response without hepatitis or to cause seroconversion without disease could not be ascertained.

The present study provides data not only on the development of hepatitis, but also on the development of serological response to H.B.V., and permits analysis of these data in terms of whether or not the recipient was initially susceptible to H.B.V. as judged by the presence of anti-HB<sub>s</sub> in the serum before transfusion. When the entire patient population was analysed, neither the risk of hepatitis B nor the frequency of serological exposure to H.B.V. was significantly greater in those transfused with anti-HB<sub>s</sub> than in those who did not receive antibody-containing blood. A similar lack of statistical association was observed when only those patients without pre-existing antibody (presumably susceptible patients) or when only patients with pre-existing antibody were analysed.

No cases of biochemical or overt hepatitis B occurred among the 84 recipients with pre-existing anti-HB<sub>s</sub>, in contrast to the 4 cases which developed among the 278 presumably susceptible recipients. Although these differences are not statistically significant, they are consistent with previous studies<sup>25,26</sup> which indicate that anicteric or icteric hepatitis B in patients with pre-existing anti-HB<sub>s</sub> is extremely unusual.

The total hepatitis risk for patients in this study was 6.4%. Only 1.1% of recipients developed hepatitis B; hence only 16% of the total hepatitis was related to H.B.V. As expected, there was no relationship between the frequency of non-type-B hepatitis and the presence of anti-HB<sub>s</sub> in either the donor or the recipient prior to transfusion.

We conclude from our data and other studies that the risk of exposure to hepatitis-B virus or of development of HB<sub>s</sub>Ag-positive hepatitis following transfusion of anti-HB<sub>s</sub>-containing blood is not significantly greater than that observed following the transfusion of blood which lacks detectable anti-HB<sub>s</sub>. The data do not support exclusion of donor blood containing anti-HB<sub>s</sub>.

This work was supported in part by contracts NIH-NHLI-

70-2231 and NIH-NHLI-71-2353 from the National Heart and Lung Institute. We thank Miss Patricia Clay, Mr Jerry Chervitz, Mrs Loma Coday, Mrs Susan Fallek, Mr James McAdam, Mrs Shirley Snowe, Ms Karen Landry, Ms Melinda Freeman, Dr Marian Fisher, and Dr Robert Purcell for technical assistance.

Requests for reprints should be addressed to J. M. W., Building 31, Room 5A-11, Blood Resources Branch, Division of Blood Diseases and Resources, National Heart and Lung Institute, Bethesda, Maryland 20014, U.S.A.

## REFERENCES

1. Alter, H. J., Holland, P. V., Purcell, R. H., Lander, J. J., Feinstone, S. M., Morrow, A. G., Schmidt, P. J. *Ann. intern. Med.* 1972, 77, 691.
2. Gocke, D. J. *J. Am. med. Ass.* 1972, 219, 1165.
3. Koretz, R. L., Klaus, D. R., Ritman, S., Damus, K. H., Gitnick, G. L. *Lancet*, 1973, ii, 694.
4. Hollinger, F. B., Aach, R. D., Gitnick, G. L., Roche, J. K., Melnick, J. L. *New Engl. J. Med.* 1973, 289, 385.
5. Holland, P. V., Alter, H. J., Purcell, R. H., Walsh, J. J., Morrow, A. G., Schmidt, P. J. in *Australia Antigen* (edited by J. E. Frier). Baltimore, 1973.
6. Roche, J. K., Stengle, J. M. *Transfusion*, 1973, 13, 258.
7. Barker, L. F., Shulman, N. R., Murray, R., Hirschman, R. J., Ratner, F., Diefenbach, W. C. L., Geller, H. M. *J. Am. med. Ass.* 1970, 211, 1509.
8. Hollinger, F. B., Werch, J., Melnick, J. L. *New Engl. J. Med.* 1974, 290, 1104.
9. Ashe, W. K., Norkins, A. L. *Proc. natn. Acad. Sci. U.S.A.* 1966, 56, 447.
10. Szmuness, W., Prince, A. M., Brotman, B., Hirsch, R. L. *J. infect. Dis.* 1973, 127, 17.
11. Lewis, T. L., Alter, H. J., Chalmers, T. C., Holland, P. V., Purcell, R. H., Alling, D. W., Young, D., Frenkel, L. D., Lee, S. L., Lamson, M. E. *New Engl. J. Med.* 1973, 289, 647.
12. Gocke, D. J., Panick, J. M. in *Hepatitis and Blood Transfusion* (edited by G. N. Vyas, H. A. Perkins, R. Schmid); p. 319. New York, 1972.
13. Caggiano, V. *ibid.* p. 323.
14. Seeff, L. B., Zimmerman, H. J., Wright, E. C., Members of Cooperative Study Group. *Gastroenterology* 1973, 64, 893.
15. Gocke, D. J., Howe, C. J. *Immun.* 1970, 104, 1031.
16. Alter, H. J., Holland, P. V., Purcell, R. H. *J. Lab. clin. Med.* 1971, 77, 1000.
17. Aach, R. D., Grisham, J. W., Parker, C. W. *Proc. natn. Acad. Sci. U.S.A.* 1971, 68, 1056.
18. Hollinger, F. B., Vorndam, V., Dreesman, G. R. *J. Immun.* 1971, 107, 1099.
19. Hollinger, F. B. *Hepatitis in Manual of Clinical Microbiology*; chapter 91. American Society for Microbiology, Washington, D.C. (in the press).
20. Ling, C. M., Overby, L. R. *J. Immun.* 1972, 109, 834.
21. Hacker, E. J., Aach, R. D. *J. Am. med. Ass.* 1973, 223, 414.
22. Vyas, G. R., Shulman, N. R. *Science*, 1970, 170, 332.
23. Weiler, J. M., Grady, G. F. *Transfusion* (in the press).
24. Goldfield, M. in *Transmissible Diseases and Blood Transfusion* (edited by T. J. Greenwalt and G. A. Jamison). New York (in the press).
25. Lander, J. J., Giles, J. P., Purcell, R. H., Krugman, S. *New Engl. J. Med.* 1971, 285, 303.
26. Greenberg, H. B., Gocke, D. J. *J. infect. Dis.* 1971, 123, 356.

## SEASONAL OCCURRENCE OF COMPLEX VENTRICULAR SEPTAL DEFECT

KENNETH J. ROTHMAN DONALD C. FYLER

Department of Epidemiology, Harvard School of Public Health, and Department of Cardiology, Children's Hospital Medical Center, Boston, U.S.A.

**Summary** The seasonal occurrence of births of children with ventricular septal defects (v.s.d.) was examined for a series of 302 cases from New England. The overall series showed a moderate peak in the summer, which was entirely attributable to a strong tendency for complex v.s.d. to occur in summer. Complex v.s.d. occurred 4.4 times more frequently in urban counties than rural counties, and the seasonal trend was strongest in urban areas. The seasonal peak was not associated with birth-weight,

Total non-type-B hepatitis\*

6.0%

11.4%

2.1%

2.0%

21

non-type-B hepatitis



0000

U.S. POSTAGE  
PAID  
LOS ANGELES, CA  
90015  
NOV 05, 99  
AMOUNT

**\$3.20**  
00054298-02

FROM **PACIFIC COAST TISSUE BANK**  
2500-19 So. Flower St. Los Angeles, CA. 90007

TO: *Food and Drug Administration  
Dockets Management Branch (HFA-305)  
5630 Fishers Lane, #1061  
Rockville, MD 20852*

MAIL

Z J58 J37 730

**CERTIFIED**

Fold at line over top of envelope to  
the right of the return address